FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome

Clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to fatality. Hence, understanding the mechanisms that cause tumor progression is crucial for the treatment of patients. In this study, we show that FOXR2 activation identifies a subset of neuroblastoma tumors wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt-Hoffner, Felix, van Rijn, Sjoerd, Toprak, Umut H., Mauermann, Monika, Rosemann, Felix, Heit-Mondrzyk, Anke, Hübner, Jens-Martin, Camgöz, Aylin, Hartlieb, Sabine, Pfister, Stefan M., Henrich, Kai-Oliver, Westermann, Frank, Kool, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500564/
https://www.ncbi.nlm.nih.gov/pubmed/34110923
http://dx.doi.org/10.1200/JCO.20.02540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500564/
https://www.ncbi.nlm.nih.gov/pubmed/34110923
http://dx.doi.org/10.1200/JCO.20.02540

Ejemplares similares